Regeneron Pharmaceuticals's quarterly market cap
increased
from Jun. 2023 ($78,249 Mil) to Sep. 2023 ($89,553 Mil) and
increased
from Sep. 2023 ($89,553 Mil) to Dec. 2023 ($96,101 Mil).
Regeneron Pharmaceuticals's annual market cap
increased
from Dec. 2021 ($68,630 Mil) to Dec. 2022 ($79,075 Mil) and
increased
from Dec. 2022 ($79,075 Mil) to Dec. 2023 ($96,101 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Regeneron Pharmaceuticals's Enterprise Value for Today is $91,365 Mil.
Regeneron Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regeneron Pharmaceuticals's Market Cap
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Market Cap falls into.
Regeneron Pharmaceuticals Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Regeneron Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (NAS:REGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Regeneron Pharmaceuticals Market Cap Related Terms
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REGN has been successfully added to your 